^
    Back
    Association details:
    Biomarker:RAS mutation
    Cancer:Thyroid Gland Medullary Carcinoma
    Drug:Cometriq (cabozantinib capsule) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Excerpt:
    In patients with RETM918T or RAS-mutant MTCs, cabozantinib offers significant PFS and OS advantages over wild-type MTCs.